March 20, 2013 / 12:12 PM / 4 years ago

Valeant to buy Obagi Medical for about $344 mln

1 Min Read

March 20 (Reuters) - Canadian drugmaker Valeant Pharmaceuticals International Inc said it would buy Obagi Medical Products Inc for about $344 million to boost its dermatology and aesthetics portfolio.

The deal, at $19.75 per share in cash, is at a 28 percent premium to Obagi's Tuesday closing price.

Obagi's board has unanimously approved the deal, Valeant said in a statement.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below